Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Safran

Showing results (41-50 of 117) with videos related to

Pageof 12
Sort By:
Translational Gastroenterology and Hepatology|May 8, 2024
Nivolumab plus ONC201 plus in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients: a Brown University Oncology Research Group phase Ib/II study (BrUOG379)Khaldoun Almhanna, Rimini Breakstone, Alexander Raufi, et al.
International Journal of Radiation Oncology, Biology, Physics|November 14, 2006
Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinomaHoward Safran, Thomas Dipetrillo, Paul Akerman, et al.
American Journal of Clinical Oncology|November 7, 2014
Complete Neoadjuvant Treatment for Rectal Cancer: The Brown University Oncology Group CONTRE StudyKimberly Perez, Howard Safran, William Sikov, et al.
Cancer|March 29, 2002
A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving boneWallace Akerley, James Butera, Terek Wehbe, et al.
The Journal of Biological Chemistry|February 8, 2003
ErbB2 degradation mediated by the co-chaperone protein CHIPPengcheng Zhou, Norvin Fernandes, Ingrid L Dodge, et al.
American Journal of Clinical Oncology|April 9, 2008
Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancerHoward Safran, Thomas Miner, Murray Resnick, et al.
American Journal of Clinical Oncology|April 26, 2021
A Pilot Study of Short-course Nivolumab and Low-dose Ipilimumab for Adjuvant Treatment of Melanoma: Brown University Oncology Research Group Trial, BrUOG 324Maria Constantinou, Thomas J Miner, John M Vatkevitch, et al.
The American Journal of Surgical Pathology|February 28, 2015
A Novel SDHA-deficient Renal Cell Carcinoma Revealed by Comprehensive Genomic ProfilingEvgeny Yakirevich, Siraj M Ali, Anthony Mega, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2019
Phase I and Pharmacology Study of Ropidoxuridine (IPdR) as Prodrug for Iododeoxyuridine-Mediated Tumor Radiosensitization in Advanced GI Cancer Undergoing RadiationTimothy Kinsella, Howard Safran, Susan Wiersma, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|December 12, 2012
Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 studyJeffrey M Hardacre, Mary Mulcahy, William Small, et al.
Pageof 12

Showing results (41-50 of 117) with videos related to

Sort By:
Pageof 12
Translational Gastroenterology and Hepatology|May 8, 2024
Nivolumab plus ONC201 plus in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients: a Brown University Oncology Research Group phase Ib/II study (BrUOG379)Khaldoun Almhanna, Rimini Breakstone, Alexander Raufi, et al.
International Journal of Radiation Oncology, Biology, Physics|November 14, 2006
Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinomaHoward Safran, Thomas Dipetrillo, Paul Akerman, et al.
American Journal of Clinical Oncology|November 7, 2014
Complete Neoadjuvant Treatment for Rectal Cancer: The Brown University Oncology Group CONTRE StudyKimberly Perez, Howard Safran, William Sikov, et al.
Cancer|March 29, 2002
A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving boneWallace Akerley, James Butera, Terek Wehbe, et al.
The Journal of Biological Chemistry|February 8, 2003
ErbB2 degradation mediated by the co-chaperone protein CHIPPengcheng Zhou, Norvin Fernandes, Ingrid L Dodge, et al.
American Journal of Clinical Oncology|April 9, 2008
Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancerHoward Safran, Thomas Miner, Murray Resnick, et al.
American Journal of Clinical Oncology|April 26, 2021
A Pilot Study of Short-course Nivolumab and Low-dose Ipilimumab for Adjuvant Treatment of Melanoma: Brown University Oncology Research Group Trial, BrUOG 324Maria Constantinou, Thomas J Miner, John M Vatkevitch, et al.
The American Journal of Surgical Pathology|February 28, 2015
A Novel SDHA-deficient Renal Cell Carcinoma Revealed by Comprehensive Genomic ProfilingEvgeny Yakirevich, Siraj M Ali, Anthony Mega, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2019
Phase I and Pharmacology Study of Ropidoxuridine (IPdR) as Prodrug for Iododeoxyuridine-Mediated Tumor Radiosensitization in Advanced GI Cancer Undergoing RadiationTimothy Kinsella, Howard Safran, Susan Wiersma, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|December 12, 2012
Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 studyJeffrey M Hardacre, Mary Mulcahy, William Small, et al.
Pageof 12